Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 2, 2023The American Journal of Drug and Alcohol AbuseOpen Access

Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JJJermaine D. JonesLRLavanya RajachandranFYFrank D. Yocca

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jones et al. (2023) studied this question.

synapsesocial.com/papers/6a7ce2816ffc6062d77bf4bbhttps://doi.org/10.1080/00952990.2022.2144743
View Full Paper
Ask AI
Bookmark
Share